CLINICAL TRIALS
Zalifrelimab: Anti-CTLA-4 Antibody
Enrolling in second-line cervical cancer
NCT03495882
Phase 1/2, open-label study of AGEN1884 in combination with AGEN2034 in subjects with locally advanced, recurrent and/or metastatic solid tumors including cervical cancer
Enrolling in cancers that have progressed after PD-1/PD-L1 inhibitor as the most recent therapy
NCT02694822
Phase 1/2, multicenter study to evaluate the safety, PK, and PD of an anti-CTLA-4 human monoclonal antibody (AGEN1884) in subjects with advanced or refractory cancer and in subjects who have progressed during treatment with a PD-1/PD-L1 inhibitor as their most recent therapy
Balstilimab: Anti-PD-1 Antibody
Enrolling in second-line cervical cancer
NCT03104699
Phase 2 expansion to evaluate efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen
Enrolling in second-line cervical cancer
NCT03894215
Randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy and safety of AGEN2034 administered with placebo (Treatment Arm 1 – monotherapy) or with AGEN1884 (Treatment Arm 2 – combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy
AGEN1181: Next-generation Anti-CTLA-4 Antibody
Enrolling in solid tumors
NCT03860272
Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of a novel Fc-engineered IgG1 anti-CTLA-4 human monoclonal antibody (AGEN1181) monotherapy and in combination with a human monoclonal IgG4 antibody (AGEN2034)
AGEN2373: CD137 agonist
Enrolling in solid tumors
NCT04121676
Phase I open-label, 3+3 dose escalation design Phase I trial to assess the safety, tolerability and dose-limiting toxicity (DLT) of AGEN2373 as monotherapy in subjects with solid tumors
AGEN1223: Regulatory T cell depletion (bispecific)
Enrolling in solid tumors
NCT04156100
Phase 1 study to evaluate the safety, tolerability, PK, and pharmacodynamic profiles of AGEN1223 and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors